Study: Mobile app therapy leads to significant improvement in fibromyalgia management

The multicenter, randomized controlled trial tested Stanza, a smartphone app that delivers acceptance and commitment therapy (ACT), a type of cognitive behavioral therapy recommended by international clinical guidelines for fibromyalgia management, with the results of the study published July 8 in The Lancet.

Fibromyalgia is a chronic pain condition that affects an estimated 10 million Americans, a majority of whom are women. The condition is characterized by widespread pain and other physical and cognitive symptoms that include fatigue, disrupted sleep, reduced physical function, memory problems and difficulty concentrating (“brain fog”). It is often accompanied by anxiety and depression.

The Phase 3 PROSPER-FM trial clinically validated Stanza’s benefits, including improvements in well-being, fibromyalgia severity and major fibromyalgia symptoms, including pain intensity, pain interference, fatigue, sleep disturbance, depression and physical function. This study is the largest medical device study for fibromyalgia ever undertaken.

“For millions of people with fibromyalgia, this study, published in The Lancet, describes a new and effective therapy for fibromyalgia,” said Lesley Arnold, MD, study principal investigator and professor emerita at the University of Cincinnati College of Medicine. “This novel, non-drug therapy, available using a smartphone, makes management of fibromyalgia more accessible and convenient. This offers new hope for people with fibromyalgia, who have continued to experience unmet treatment needs.”

In the 12-week trial, 275 participants were randomized to receive either Stanza treatment or a digital symptom tracker control. At week 12, 70.6% of participants in the Stanza arm reported an improvement on Patient Global Impression in Change, which measures patient well-being.